Clinical-Microbiomics A/S - Group

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 2.0% 1.9%  
Credit score (0-100)  0 0 0 68 69  
Credit rating  N/A N/A N/A A A  
Credit limit (kEUR)  0.0 0.0 0.0 1.8 19.9  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kEUR) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 2,760 6,221  
EBITDA  0.0 0.0 0.0 -631 878  
EBIT  0.0 0.0 0.0 -1,119 -2,313  
Pre-tax profit (PTP)  0.0 0.0 0.0 -1,390.0 -2,606.0  
Net earnings  0.0 0.0 0.0 -1,336.0 -2,542.0  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -1,390 -2,606  

 
See the entire income statement

Balance sheet (kEUR) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 2,337 3,806  
Shareholders equity total  0.0 0.0 0.0 15,638 85,160  
Interest-bearing liabilities  0.0 0.0 0.0 3,334 3,303  
Balance sheet total (assets)  0.0 0.0 0.0 22,891 102,905  

Net Debt  0.0 0.0 0.0 -3,032 1,481  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 2,760 6,221  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 125.4%  
Employees  0 0 0 43 82  
Employee growth %  0.0% 0.0% 0.0% 0.0% 90.7%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 22,891 102,905  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% 349.5%  
Added value  0.0 0.0 0.0 -1,119.0 878.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 14,226 76,751  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 -2.0  

Profitability 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% -40.5% -37.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% -4.8% -3.7%  
ROI %  0.0% 0.0% 0.0% -5.3% -3.9%  
ROE %  0.0% 0.0% 0.0% -8.5% -5.0%  

Solidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% 68.3% 82.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 480.5% 168.7%  
Gearing %  0.0% 0.0% 0.0% 21.3% 3.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 17.4% 9.3%  

Liquidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 2.0 0.9  
Current Ratio  0.0 0.0 0.0 2.0 1.0  
Cash and cash equivalent  0.0 0.0 0.0 6,366.0 1,822.0  

Capital use efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 16.0 -308.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -26 11  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -15 11  
EBIT / employee  0 0 0 -26 -28  
Net earnings / employee  0 0 0 -31 -31